lundi 16 mars 2020

Onco Actu du 16 mars 2020


4.1 DÉP., DIAG. & PRONO. - PROSTATE



Prostate Cancer Detection From Urine RNA, Metabolites Shows Promise [Genome Web]











4.12 BIOPSIES LIQUIDES



Liquid Biopsy Assays Targeting More Patient-Specific Mutations Improve Recurrence Prediction [Genome Web]











Blood biopsies offer early warning of cancer’s return [Harvard Gazette]










4.2 DÉP., DIAG. & PRONO. - GÉNOME



DNA tests grow more vital in hereditary breast cancer treatments. They also raise unanswerable questions. [Washington Post]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Novartis sidesteps Europe travel ban to provide CAR-T drug Kymriah to patients [Fierce Pharma]











Novartis secures alternate options for Kymriah shipments after Europe travel ban [Reuters]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Pfizer, Merck KGaA’s Bavencio skewered by Javelin in head and neck cancer [Fierce Pharma]











5.12.6 IMMUNOTHÉRAPIES - AMM



FDA Grants Accelerated Approval to Nivolumab and Ipilimumab Combination for Hepatocellular Carcinoma [ESMO]











5.2 PHARMA



New uncommon EGFR mutations database published featuring clinical outcomes of NSCLC patients treated with afatinib [Boehringer Ingelheim]











5.3 TRAITEMENTS - FDA, EMA,...



Inappropriate use of progression-free survival in cancer drug approvals [BMJ]










6. LUTTE CONTRE LES CANCERS



Is your cancer center ready for COVID-19? [The Cancer Letter]











COVID-19 and the cancer patient: A call to action for balancing cancer care and viral risk [The Cancer Letter]










6.1 OBSERVATION



Rise in breast cancer fueled by more than later pregnancy, lower birth rate [UPI]